Human Integrin α4β1 / VCAM-1 Inhibitor Screening Kit (TR-FRET)AI Compatible

Customer Reviews
Cat. No. / Size
Price
Availability
Qty
FRT-P049-100tests
$770.00
In Stock - Delivery in 2-3 weeks
FRT-P049-500tests
$2080.00
In Stock - Delivery in 2-3 weeks

Product Details

  • FAB

    1. Comprehensive validation - Validated with various antibody drugs.
    2. Simple and fast operation - No complicated washing steps, significantly reducing time.
    3. High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
    4. Accurate and reliable results - High sensitivity with minimal matrix effects.
    5. High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
    6. Fast completion - Results in just 1.5 hours.
  • Product Specifications

    Assay Type
    Competition-TR-FRET
    Reactivity
    Human
    Regulatory Status
    RUO
    Assay Time
    1.5 hr
    Sample volume
    10 μL

  • Product Overview

    The Human Integrin α4β1 / VCAM-1 Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screen for inhibitors of human integrin α4β1 binding to VCAM-1 within 1.5 hours. It can also be used as a universal detection tool to identify the ability of human integrin α4β1 to bind to human VCAM-1.

  • Storage

    1. Store the unopened kit at 2-8°C upon receipt.

    2. Locate the expiration date on the outer packaging and do not use reagents beyond their expiration date.

    3. The opened kit should be stored according to the storage conditions listed in the Components Table. The shelf life of the opened kit is 30 days from the date of opening.

  • Materials Provided

    ID
    Components
    Size
    FRTP049-C01
    Human VCAM-1 Protein Europium-chelate
    100 tests/500 tests
    FRTP049-C02
    FA Labeled Human Integrin α4β1 Protein
    100 tests/500 tests
    FRTP049-C03
    Anti-Human Integrin α4β1 Neutralizing Antibody
    30 μg/100 tests
    150 μg/500 tests
    FRTP049-C04
    TR-FRET Sample Dilution Buffer, pH7.4
    50 mL/100 tests & 500 tests
    FRTP049-C05
    TR-FRET Detection Buffer, pH7.4
    50 mL/100 tests & 500 tests
    FRTP049-C06
    Signal Enhancer
    8 mL/100 tests & 500 tests

  • Assay Principles

    This Human Integrin α4β1 / VCAM-1 Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human VCAM-1 and Europium-chelate labeled streptavidin as the Donor and FA Labeled Human Integrin α4β1 Protein as the Acceptor.

    — When the sample does not contain the inhibitors that block the binding of human Integrin α4β1 to human VCAM-1, the Donor and Acceptor are in close proximity because of the binding of human Integrin α4β1 and human VCAM-1. Upon Donor excitation with light of a specific wavelength (337 nm), in addition to Donor emission (620 nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665 nm).

    — When the sample contains the inhibitors that block the binding of human Integrin α4β1 to human VCAM-1, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.

    Assay Principles
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-TR-FRET 

    Please refer to DS document for the assay protocol.

     Integrin alpha 4 beta 1 TR-FRET

    In this TR-FRET assay, Human VCAM-1 Protein Europium-chelate is used as the Donor and FA Labeled Human Integrin α4β1 Protein is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between human Integrin α4β1 and human VCAM-1 using Anti-Human Integrin α4β1 Neutralizing Antibody resulting in a typical IC50 of 2.878 nM (QC tested).

  •  Integrin alpha 4 beta 1 TR-FRET

    The kit is suitable for the detection and characterization of Integrin α4β1 / VCAM-1 inhibitors. It was shown that the anti Integrin α4β1 antibody (Natalizumab) disrupted the interaction, with an IC50 of 2.737 nM. The anti-TNF-alpha antibody (Adalimumab) showed no significant inhibitory effect in the assay as expected.

Customer Reviews
Writing Reviews

Recent Advances

 
Drug Development Progress
  • English Name:

    Integrin alpha-4/beta-1

  • Category:

  • Approved Drugs:

    3 Details

  • Drugs in Clinical Trials:

    6 Details

  • Highest Development Stage:

    Approved

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8